Cite
HARVARD Citation
Mease, P. et al. (2018). Secukinumab in the treatment of psoriatic arthritis: efficacy and safety results through 3 years from the year 1 extension of the randomised phase III FUTURE 1 trial. RMD open. 4 (2), p. . [Online].